Campbell & CO Investment Adviser LLC Makes New $673,000 Investment in Takeda Pharmaceutical Co. $TAK

Campbell & CO Investment Adviser LLC acquired a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 45,981 shares of the company’s stock, valued at approximately $673,000.

Several other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada boosted its position in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC lifted its position in Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after buying an additional 59,442 shares during the period. Goldman Sachs Group Inc. lifted its position in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares during the period. Focus Partners Wealth boosted its holdings in shares of Takeda Pharmaceutical by 4.1% during the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after buying an additional 3,239 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in shares of Takeda Pharmaceutical in the 2nd quarter worth about $351,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK opened at $16.16 on Wednesday. The company has a market cap of $51.40 billion, a PE ratio of 201.94 and a beta of 0.03. The firm’s 50-day moving average price is $15.02 and its 200-day moving average price is $14.71. Takeda Pharmaceutical Co. has a 52-week low of $12.80 and a 52-week high of $16.48. The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.61.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.44. The company had revenue of $7.30 billion for the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical had a return on equity of 10.32% and a net margin of 0.86%.Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. As a group, analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TAK. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating for the company. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.